Nrx pharmaceuticals provides update on breakthrough therapy designation (btd) request for zyesami® (aviptadil)

Radnor, pa. , june 10, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp, nrx pharmaceuticals), ("nrxp" or the "company"), a clinical-stage biopharmaceutical company, today announced that the u.s. food and drug administration (fda) denied the breakthrough therapy designation (btd) request for zyesami® (aviptadil) and emphasized its focus on the company's nrx-101 btd compound for bipolar depression associated with suicidality.
NRXP Ratings Summary
NRXP Quant Ranking